Clinical Trials Logo

EBV clinical trials

View clinical trials related to EBV.

Filter by:
  • Not yet recruiting  
  • Page 1

NCT ID: NCT05677178 Not yet recruiting - Clinical trials for Hemophagocytic Lymphohistiocytoses

Response Prediction in EBV-HLH Using Metabonomics Analysis

Start date: January 1, 2023
Phase:
Study type: Observational [Patient Registry]

Hemophagocytic lymphohistiocytosis (HLH) is a rare, poorly recognized and underdiagnosed syndrome of excessive immune activation, which is rapidly fatal. Epstein-Barr virus (EBV) is a common trigger of HLH, particularly in Asian individuals. We aim to analyze metabolomics and cytokine profiles of patients before and after treatment to explore the metabolomic characteristics of EBV-HLH, and search for pathogenic mechanisms and therapeutic targets.

NCT ID: NCT02878278 Not yet recruiting - EBV Clinical Trials

Differences Between Chidamide Taken Daily and Twice a Week in Therapeutic Effect,Pharmacokinetics, Pharmacodynamics and EB Virus Activation

Start date: September 2016
Phase: Phase 2
Study type: Interventional

1. To compare the therapeutic effects, safety and the corresponding pharmacokinetics and pharmacodynamics between two different method of drug administration: 10mg, daily and 30mg/d, twice every week, and find out the more effect way of Chidamide administration. 2. To examine whether Chidamide could activate EB virus, and whether the above two different ways of administration are different in EB virus activation.